4.7 Article

A biocompatible bismuth based metal-organic framework as efficient light-sensitive drug carrier

期刊

JOURNAL OF COLLOID AND INTERFACE SCIENCE
卷 617, 期 -, 页码 578-584

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.jcis.2022.01.188

关键词

Drug carrier; Bismuth based metal-organic framework; Biocompatible materials; Controlled release

资金

  1. National Key Research and Development Program of China [2020YFA0710301]
  2. National Natural Science Foundation of China [U1832145, 22172088, 51972195, 21832005, 21972078, 11374190]
  3. Young Scholars Program of Shandong University [2020QNQT012]
  4. Shandong Province Natural Science Foundation [ZR2020YQ16]
  5. Taishan Scholar Foundation of Shandong Province, China

向作者/读者索取更多资源

Bismuth-based metal-organic framework SU-101 shows high drug loading and controlled drug release under light illumination, attributed to the hydrogen bond interaction between C=O and -OH groups. The study suggests the potential of SU-101 as a light-sensitive drug carrier for various drugs.
The low toxicity and good photo active property endow bismuth based metal-organic frameworks (MOFs) potential candidates for efficient light-sensitive drug carrier. In this work, SU-101, composed of Bi and ellagic acid (EA), is found to display high ciprofloxacin (CIP) loading ratio (85.8%) and controlled CIP release under light illumination (the maximum CIP release ratio is 95.56%). Further investigations suggest that hydrogen bond between the C=O group in EA and the -OH group in CIP is responsible for above behavior. Light irradiation decreases the electron density around the C=O group in EA, which consequently leads to the broken of the hydrogen bond and therefore the release of CIP. Further investigations suggest that SU-101 is universal for other drugs, such as norfloxacin (NOR), amoxicillin (AMO), tetracycline (TET) and doxorubicin hydrochloride (DOX), since all of them can form hydrogen bond with SU-101. This work suggests that SU-101 holds great potential as efficient light-sensitive drug carrier, and the investigation of other Bi based MOFs as drug carrier is under investigation.(c) 2022 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据